Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03913949 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Completion date: Dec 31, 2025 to Dec 31, 2026v10
  2. Primary completion date changed from estimate of Dec 31, 2024 to Oct 20, 2024v9
  3. Primary completion date: Dec 31, 2023 to Dec 31, 2024 Completion date: Dec 31, 2024 to Dec 31, 2025v8 Show 1 more changeShow less
    • Completion date: Dec 31, 2024 to Dec 31, 2025
  4. Primary completion date: Sep 2022 to Dec 31, 2023 Trial status: Recruiting to Active, Not Recruiting · Completion date: Dec 2023 to Dec 31, 2024 · Site details revised at 5 of 5 sitesv7 Show 3 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Completion date: Dec 2023 to Dec 31, 2024
    • Site details revised at 5 of 5 sites
  5. Primary completion date: Dec 2021 to Sep 2022 Enrollment target: 90 to 74 · Completion date: Dec 2022 to Dec 2023v6 Show 2 more changesShow less
    • Enrollment target: 90 to 74
    • Completion date: Dec 2022 to Dec 2023
Show 4 earlier versionsHide 4 earlier versions
  1. Primary completion date: Mar 2021 to Dec 2021 Study sites: 1 to 5 · Completion date: Mar 2022 to Dec 2022v5 Show 2 more changesShow less
    • Study sites: 1 to 5
    • Completion date: Mar 2022 to Dec 2022
  2. Collaborators expanded, about 5 wordsv4 See this version in full on ClinicalTrials.gov ↗
  3. Re-verified, no change to tracked fieldsv3
  4. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Apr 2019 to Jun 3, 2019 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Apr 2019 to Jun 3, 2019
    • Site details revised
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic properties of APG-2575 in patients with relapse or refractory chronic lymphocytic leukemia and non-hodgkin's lymphoma.
Trial Details
NCT Number NCT03913949
Lead Sponsor Ascentage Pharma Group Inc.
Collaborators: Suzhou Yasheng Pharmaceutical Co., Ltd.
Conditions Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Enrollment 74 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov